★
Trade Filings
Managers Aandelen Ingediende stukken Superinvesteerders
Signalen Institutionele aankopen Institutionele verkopen Insider-activiteit 13D & 13G Watch Sectorrotatie
Tools Aandelenscreener Manager Screener Beheerders vergelijken Consensusmandjes Alle onderzoekstools Data-API
Leren & AI Leren Vraag de data AI-agents
Nieuws ★ Opgeslagen
Over Over ons Methodologie Contact Disclaimer
Reader
DATAPAKKETTEN

Downloads van historische gegevens — beschikbaar met accounts.

API GATEWAY

Gratis alleen-lezen JSON-toegang tot de gecachede gegevens van de site.
Donkere modus

🧭 Begeleide weergave
Nieuw met markten — koersen, yields, YTD, marktkapitalisatie? We leggen elk begrip uit terwijl u bladert, in begrijpelijke taal. Dezelfde data, met ingebouwde uitleg.

⚡ Expertvisie
U kent de markt al. Alleen de data — schoon, snel en compact, zonder extra uitleg. Dit is de standaardweergave.

Interfacetaal
Effectdossier · gearchiveerd kwartaal

LLY

Eli Lilly and Company · Healthcare · Drug Manufacturers - General

1,233.5 -1.1% marktkapitalisatie $1.16T koers vertraagd (FMP) · per Aug 25 22:08 UTC — los van onderstaande aangiftegegevens

Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024
193Gevolgde houders
+2Δ houders
707.04MGehouden aandelen
$758.81BGerapporteerde waarde
+3Nieuwe posities
−0Uitstappen
Stable Overtuigingsscore 55/100 3 kwartalen van stijgende gevolgde aandelen ●●●○○○ Hoe deze worden berekend → Dit toelichten aan de Research Desk →

Momentum-inputs (vergelijkbare managers): breedte van houders +1.0% · aandelenstroom -0.6% · netto nieuwe posities +1.6% — formule
Versnippering van eigendom — meer houders, kleinere totale positie

Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q4 2025

Eigendom in de tijd
KwartaalHoudersΔAandelenGerapporteerde waardeNieuwUitstappen
Q2 2026 193 +4 671.92M $804.91B +6 −1
Q1 2026 191 -3 666.59M $613.20B +1 −5
Q4 2025 193 +2 707.04M $758.81B +3 —
Q3 2025 27 -3 329.88M $251.63B +2 −6
Q2 2025 28 -1 307.45M $239.60B +2 −3
Q1 2025 26 0 140.32M $115.83B +1 −1
Q4 2024 26 +1 145.00M $111.91B +3 −2
Q3 2024 24 +2 109.89M $97.29B +2 —
Q2 2024 22 — 112.43M $101.75B — —
Aantal houders
Wie het bezit · Q4 2025
#ManagerAandelenΔ aandelenWaardeHun gewichtGehouden
1 Lilly Endowment Inc 92.19M — $99.08B 100.0% n/c 1 SEC ↗
2 The Vanguard Group ✦ (passief) 81.97M +1.2% $88.09B 1.3% ▲ Add 3 SEC ↗
3 The Vanguard Group ✦ (passief) 81.97M +1.2% $88.09B 1.3% ▲ Add 3 SEC ↗
4 The Vanguard Group ✦ (passief) 81.97M +1.2% $88.09B 1.3% ▲ Add 3 SEC ↗
5 The Vanguard Group ✦ (passief) 81.97M +1.2% $88.09B 1.3% ▲ Add 3 SEC ↗
6 The Vanguard Group ✦ (passief) 81.97M +1.2% $88.09B 1.3% ▲ Add 3 SEC ↗
7 The Vanguard Group ✦ (passief) 81.97M +1.2% $88.09B 1.3% ▲ Add 3 SEC ↗
8 The Vanguard Group ✦ (passief) 81.97M +1.2% $88.09B 1.3% ▲ Add 3 SEC ↗
9 BlackRock ✦ (passief) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
10 BlackRock ✦ (passief) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
11 BlackRock ✦ (passief) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
12 BlackRock ✦ (passief) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
13 BlackRock ✦ (passief) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
14 BlackRock ✦ (passief) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
15 BlackRock ✦ (passief) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
16 BlackRock ✦ (passief) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
17 BlackRock ✦ (passief) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
18 BlackRock ✦ (passief) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
19 BlackRock ✦ (passief) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
20 BlackRock ✦ (passief) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
21 BlackRock ✦ (passief) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
22 BlackRock ✦ (passief) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
23 BlackRock ✦ (passief) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
24 BlackRock ✦ (passief) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
25 BlackRock ✦ (passief) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
26 BlackRock ✦ (passief) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
27 BlackRock ✦ (passief) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
28 BlackRock ✦ (passief) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
29 BlackRock ✦ (passief) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
30 BlackRock ✦ (passief) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
31 BlackRock ✦ (passief) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
32 BlackRock ✦ (passief) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
33 Pnc Financial Services Group, Inc. 51.33M — $55.17B 30.1% n/c 1 SEC ↗
34 Pnc Financial Services Group, Inc. 51.33M — $55.17B 30.1% n/c 1 SEC ↗
35 Pnc Financial Services Group, Inc. 51.33M — $55.17B 30.1% n/c 1 SEC ↗
36 Pnc Financial Services Group, Inc. 51.33M — $55.17B 30.1% n/c 1 SEC ↗
37 Pnc Financial Services Group, Inc. 51.33M — $55.17B 30.1% n/c 1 SEC ↗
38 Pnc Financial Services Group, Inc. 51.33M — $55.17B 30.1% n/c 1 SEC ↗
39 Pnc Financial Services Group, Inc. 51.33M — $55.17B 30.1% n/c 1 SEC ↗
40 Pnc Financial Services Group, Inc. 51.33M — $55.17B 30.1% n/c 1 SEC ↗
41 Pnc Financial Services Group, Inc. 51.33M — $55.17B 30.1% n/c 1 SEC ↗
42 Pnc Financial Services Group, Inc. 51.33M — $55.17B 30.1% n/c 1 SEC ↗
43 Pnc Financial Services Group, Inc. 51.33M — $55.17B 30.1% n/c 1 SEC ↗
44 State Street Global Advisors ✦ (passief) 35.36M +1.8% $38.00B 1.3% ▲ Add 5 SEC ↗
45 Fidelity (FMR) ✦ 25.72M +6.4% $27.64B 1.4% ▲ Add 3 SEC ↗
46 Fidelity (FMR) ✦ 25.72M +6.4% $27.64B 1.4% ▲ Add 3 SEC ↗
47 Fidelity (FMR) ✦ 25.72M +6.4% $27.64B 1.4% ▲ Add 3 SEC ↗
48 Fidelity (FMR) ✦ 25.72M +6.4% $27.64B 1.4% ▲ Add 3 SEC ↗
49 Fidelity (FMR) ✦ 25.72M +6.4% $27.64B 1.4% ▲ Add 3 SEC ↗
50 Fidelity (FMR) ✦ 25.72M +6.4% $27.64B 1.4% ▲ Add 3 SEC ↗
51 Capital Research Global Investors 24.57M — $26.40B 4.9% n/c 1 SEC ↗
52 Geode Capital Management ✦ (passief) 19.81M 0.0% $21.22B 1.3% ▼ Trim 7 SEC ↗
53 Geode Capital Management ✦ (passief) 19.81M 0.0% $21.22B 1.3% ▼ Trim 7 SEC ↗
54 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
55 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
56 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
57 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
58 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
59 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
60 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
61 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
62 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
63 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
64 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
65 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
66 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
67 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
68 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
69 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
70 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
71 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
72 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
73 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
74 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
75 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
76 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
77 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
78 Capital World Investors ✦ 15.03M +0.4% $16.15B 2.2% ▲ Add 7 SEC ↗
79 T. Rowe Price ✦ 14.91M +10.6% $16.02B 1.7% ▲ Add 7 SEC ↗
80 T. Rowe Price ✦ 14.91M +10.6% $16.02B 1.7% ▲ Add 7 SEC ↗
81 Wellington Management ✦ 13.36M -8.3% $14.35B 2.5% ▼ Trim 7 SEC ↗
82 Wellington Management ✦ 13.36M -8.3% $14.35B 2.5% ▼ Trim 7 SEC ↗
83 Wellington Management ✦ 13.36M -8.3% $14.35B 2.5% ▼ Trim 7 SEC ↗
84 Wellington Management ✦ 13.36M -8.3% $14.35B 2.5% ▼ Trim 7 SEC ↗
85 Wellington Management ✦ 13.36M -8.3% $14.35B 2.5% ▼ Trim 7 SEC ↗
86 Wellington Management ✦ 13.36M -8.3% $14.35B 2.5% ▼ Trim 7 SEC ↗
87 Wellington Management ✦ 13.36M -8.3% $14.35B 2.5% ▼ Trim 7 SEC ↗
88 Wellington Management ✦ 13.36M -8.3% $14.35B 2.5% ▼ Trim 7 SEC ↗
89 Wellington Management ✦ 13.36M -8.3% $14.35B 2.5% ▼ Trim 7 SEC ↗
90 JPMorgan Chase ✦ 13.00M -36.7% $13.97B 0.9% ▼ Trim 2 SEC ↗
91 JPMorgan Chase ✦ 13.00M -36.7% $13.97B 0.9% ▼ Trim 2 SEC ↗
92 JPMorgan Chase ✦ 13.00M -36.7% $13.97B 0.9% ▼ Trim 2 SEC ↗
93 JPMorgan Chase ✦ 13.00M -36.7% $13.97B 0.9% ▼ Trim 2 SEC ↗
94 JPMorgan Chase ✦ 13.00M -36.7% $13.97B 0.9% ▼ Trim 2 SEC ↗
95 JPMorgan Chase ✦ 13.00M -36.7% $13.97B 0.9% ▼ Trim 2 SEC ↗
96 JPMorgan Chase ✦ 13.00M -36.7% $13.97B 0.9% ▼ Trim 2 SEC ↗
97 JPMorgan Chase ✦ 13.00M -36.7% $13.97B 0.9% ▼ Trim 2 SEC ↗
98 JPMorgan Chase ✦ 13.00M -36.7% $13.97B 0.9% ▼ Trim 2 SEC ↗
99 JPMorgan Chase ✦ 13.00M -36.7% $13.97B 0.9% ▼ Trim 2 SEC ↗
100 JPMorgan Chase ✦ 13.00M -36.7% $13.97B 0.9% ▼ Trim 2 SEC ↗

"Hun gewicht" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die beheerder — de overtuigingsmaatstaf. ✦ = gecureerde beheerder.

Nieuwe kopers

Geen nieuwe bijgehouden kopers dit kwartaal.

Verlaten

Geen bijgehouden uitstappen dit kwartaal.

Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 4,323 houders, 762.84M aandelen, $674.93B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.

Vaak gezamenlijk in bezit

Wat de gevolgde houders van dit effect verder het vaakst bezitten — aantallen gedeeld eigendom, geen fundamentele relaties.

AMZN191gedeelde houders MSFT190gedeelde houders GOOGL189gedeelde houders NVDA187gedeelde houders META187gedeelde houders
Insider-transacties

Open-market aankopen (P)

Geen open-market insider-aankopen in ons dekkingsvenster.

Open-market verkopen (S)

Aug 17 Jonsson Patrik

Officer · 6.50K aand · $7.64M

Aug 10 Zakrowski Donald A

Officer · 2.00K aand · $2.37M

Aug 07 Hakim Anat

Officer · 5.00K aand · $5.95M

Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie

Beneficial ownership
Jul 23 SC 13G/A — LILLY ENDOWMENT INC

Originele SEC-indiening bekijken ↗
In het nieuws
Aug 24 FDA Clears Roche And Eli Lilly's Alzheimer's Blood Test ↗

The Food and Drug Administration has cleared a new blood test from Roche and Eli Lilly designed to help identify…

 Forbes
Aug 24 FDA Approves Alzheimer's Blood Test Developed by Roche and Eli Lilly ↗

The Food and Drug Administration cleared a blood test for identifying Alzheimer's disease symptoms, which was developed…

 WSJ
Aug 24 Roche, Eli Lilly's Alzheimer's blood test gets FDA clearance ↗

The U.S. Food and Drug Administration has cleared Roche and partner Eli Lilly's blood test to help ​identify signs of…

 Reuters
Aug 24 Eli Lilly Launches Foundayo Weight-Loss Pill in U.K. ↗

The once-daily pill was approved for patients with a body mass index of at least 30, or between 27 and 30 in the event…

 WSJ
Aug 23 Eli Lilly launches oral weight-loss pill Foundayo in UK ↗

Eli Lilly said on Monday it has launched its oral pill, ​Foundayo, in the UK for weight ‌management and type 2…

 Reuters
Herkomst: Eigendom op basis van geparseerde 13F common-stockposities (gevolgde universum, vergelijkbare sets voor wijzigingen); insider-rijen afkomstig van formulieren 3/4/5; belangen uit Schedules 13D/13G; elke indiening verwijst naar het origineel op SEC EDGAR. Rapportageperiode: Q4 2025 · Methodologie · Verkrijg dit via de API